Werewolf Therapeutics Inc (HOWL) Stock Price, Quote & News

Company Profile

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activa...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 952 0555

Website: werewolftx.com

Address:

200 Talcott Ave, 2nd Floor, Watertown, United States

Barryman1 Feb. 25 at 2:54 PM

$XWEL Nice 💪 👀 $HOWL Be early 😉 https://x.com/bkfviking123/status/2026569123241644123?s=46

0 · Reply

Barryman1 Feb. 25 at 1:39 PM

$AREB 💪 👀 $HOWL

0 · Reply

Barryman1 Feb. 25 at 1:21 PM

$HOWL both Posts below from X

0 · Reply

Barryman1 Feb. 25 at 1:21 PM

Media calls $HOWL a fire sale. Dead wrong. WTX-330 is the Holy Grail of oncology. They delivered systemic IL-12 at 23x the historic max dose & shrank treatment-resistant metastatic gallbladder cancer by 45%. Piper Sandler is here to start a Big Pharma bidding war.

0 · Reply

Barryman1 Feb. 25 at 1:20 PM

$HOWL $HOWL totally plausible in a deal scenario. $2 would be ~$97M market cap — basically cash + ~$30M premium for the assets/IP. Happens all the time in these situations (buyers love grabbing clinical-stage programs + a big cash pile to fund them). Could be higher

0 · Reply

Barryman1 Feb. 25 at 1:19 PM

$HOWL jut buy now you can at these low prices https://x.com/bkfviking123/status/2026568883079893487?s=46

0 · Reply

_Moony4x Feb. 25 at 9:38 AM

Caught a few of @TheMorningStew plays over the last few weeks that went crazy! Give him a follow 🔥 $SANM $AIDX $HOWL $RPGL bets

0 · Reply

zawojak Feb. 25 at 6:38 AM

$HOWL lol we soon find out which big hedges left during fake pump and HALT made for them.

0 · Reply

longshot45 Feb. 25 at 12:02 AM

$HOWL So based on the announcement, it is a news event about something they have been announcing for the last 6+ months… exploring strategic alternatives. I guess the only difference is now they announced who they have hired to help evaluate options

0 · Reply

LabPsycho Feb. 24 at 11:58 PM

$HOWL I've come up with The BioGrifter's Wealth Transfer Vehicle Creed: Now that the stock is down over 95% from historic highs, and some insiders have sold on the way down and near historic lows...now...now we care about strategic alternatives to advance the platform to ' maximize stockholder value'.

0 · Reply

Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives

Dec 18, 2025, 8:00 AM EST - 2 months ago

Werewolf Therapeutics Announces Pipeline and Business Updates

Nov 7, 2025, 9:00 AM EST - 3 months ago

Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Nov 4, 2025, 7:00 AM EST - 4 months ago

Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 8, 2025, 8:00 AM EDT - 5 months ago

Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer

Oct 3, 2025, 9:00 AM EDT - 5 months ago

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Sep 2, 2025, 8:00 AM EDT - 6 months ago

Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 7:00 AM EDT - 7 months ago

Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 9, 2025, 8:00 AM EDT - 8 months ago

Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit

Jun 12, 2025, 8:00 AM EDT - 9 months ago

Werewolf Therapeutics to Participate in the BIO International Convention

May 29, 2025, 8:00 AM EDT - 9 months ago

Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference

May 20, 2025, 4:01 PM EDT - 10 months ago

HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124

May 13, 2025, 8:00 AM EDT - 10 months ago

Werewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development Summit

May 8, 2025, 7:00 AM EDT - 10 months ago

Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 8:05 AM EDT - 10 months ago

Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

May 5, 2025, 8:00 AM EDT - 10 months ago

Werewolf Therapeutics to Participate in Upcoming Investor Conferences

Apr 17, 2025, 8:00 AM EDT - 11 months ago

Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer

Mar 31, 2025, 8:00 AM EDT - 11 months ago

Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 11, 2025, 7:00 AM EDT - 1 year ago

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 4, 2025, 8:00 AM EST - 1 year ago

Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference

Feb 24, 2025, 7:30 AM EST - 1 year ago

Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors

Jan 13, 2025, 8:00 AM EST - 1 year ago

Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook

Nov 20, 2024, 8:00 AM EST - 1 year ago

Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference

Nov 7, 2024, 9:02 AM EST - 1 year ago

Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Oct 4, 2024, 9:00 AM EDT - 1 year ago

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Aug 8, 2024, 7:05 AM EDT - 1 year ago

Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 1, 2024, 10:04 AM EDT - 1 year ago

Werewolf Therapeutics: Continuing To Advance And Show More Promise In Phase 1

Jun 25, 2024, 7:00 AM EDT - 1 year ago

Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

Jun 1, 2024, 9:00 AM EDT - 1 year ago

Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors

May 30, 2024, 8:00 AM EDT - 1 year ago

Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference

May 23, 2024, 5:00 PM EDT - 1 year ago

Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting

May 3, 2024, 7:00 AM EDT - 1 year ago

Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 24, 2024, 10:05 AM EDT - 2 years ago

Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

Apr 5, 2024, 4:30 PM EDT - 2 years ago

Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting

Apr 4, 2024, 4:57 PM EDT - 2 years ago

Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space

Apr 4, 2024, 4:30 PM EDT - 2 years ago

Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting

Mar 7, 2024, 7:00 AM EST - 2 years ago

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 6, 2024, 8:00 AM EST - 2 years ago

Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference

Mar 5, 2024, 4:30 PM EST - 2 years ago

Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024

Jan 8, 2024, 7:00 AM EST - 2 years ago

Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook

Jan 4, 2024, 4:05 PM EST - 2 years ago

Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors

Dec 28, 2023, 7:09 PM EST - 2 years ago

Werewolf Therapeutics: Still In The Race To Develop Next Generation Cytokines

Nov 22, 2023, 7:00 AM EST - 2 years ago

Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference

Nov 14, 2023, 4:25 PM EST - 2 years ago

Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 6, 2023, 5:14 PM EST - 2 years ago

Werewolf Therapeutics: Possibly A Transformative IL-2, But Still Early Days

Nov 3, 2023, 7:00 AM EDT - 2 years ago

Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Oct 31, 2023, 9:00 AM EDT - 2 years ago

Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 27, 2023, 9:00 AM EDT - 2 years ago

Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 11, 2023, 4:05 PM EDT - 2 years ago

Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124

Barryman1 Feb. 25 at 2:54 PM

$XWEL Nice 💪 👀 $HOWL Be early 😉 https://x.com/bkfviking123/status/2026569123241644123?s=46

0 · Reply

Barryman1 Feb. 25 at 1:39 PM

$AREB 💪 👀 $HOWL

0 · Reply

Barryman1 Feb. 25 at 1:21 PM

$HOWL both Posts below from X

0 · Reply

Barryman1 Feb. 25 at 1:21 PM

0 · Reply

Barryman1 Feb. 25 at 1:20 PM

0 · Reply

Barryman1 Feb. 25 at 1:19 PM

$HOWL jut buy now you can at these low prices https://x.com/bkfviking123/status/2026568883079893487?s=46

0 · Reply

_Moony4x Feb. 25 at 9:38 AM

Caught a few of @TheMorningStew plays over the last few weeks that went crazy! Give him a follow 🔥 $SANM $AIDX $HOWL $RPGL bets

0 · Reply

zawojak Feb. 25 at 6:38 AM

$HOWL lol we soon find out which big hedges left during fake pump and HALT made for them.

0 · Reply

longshot45 Feb. 25 at 12:02 AM

0 · Reply

LabPsycho Feb. 24 at 11:58 PM

0 · Reply

Believer1975 Feb. 24 at 10:28 PM

$HOWL maybe they have the FDA approval. Early 2026 for the decision.

0 · Reply

barney00 Feb. 24 at 10:19 PM

$HOWL

0 · Reply

jskstocks Feb. 24 at 10:15 PM

$HOWL that was surprising action, not alot of volume considering, I would not be surprised to see this go back up premarket, that is just how it goes sometimes

0 · Reply

Barryman1 Feb. 24 at 10:10 PM

$HOWL lol why halt up in AH and then it goes down

1 · Reply

jskstocks Feb. 24 at 9:52 PM

$HOWL Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives https://www.globenewswire.com/news-release/2026/02/24/3244045/0/en/Werewolf-Therapeutics-Announces-Plan-to-Explore-Strategic-Alternatives.html

0 · Reply

jskstocks Feb. 24 at 9:42 PM

$HOWL guys they had over $50MM cash at the end of 2025 and a healthy but early pipeline, current market cap is $35M, you do the math

0 · Reply

Barryman1 Feb. 24 at 9:36 PM

$HOWL news coming ?

0 · Reply

DaSqueeza Feb. 24 at 9:30 PM

$HOWL and down we go

0 · Reply

Universal6999 Feb. 24 at 9:29 PM

$HOWL what's the price people

0 · Reply

Nmiller33 Feb. 24 at 9:28 PM

$HOWL I’ll say goes to a dollar after half and then stays steady around there until 8 but we shall see

0 · Reply

FrankyNyc Feb. 24 at 9:22 PM

$HOWL it halted at 0.82??

0 · Reply

Market Cap	32.11M
Revenue (ttm)	1.89M
Net Income (ttm)	-70.52M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,731.22%
Debt to Equity Ratio	0.73

Volume	337,000
Avg Vol	662,084
Day's Range	N/A - N/A
Shares Out	48.54M
Stochastic %K	17%
Beta	0.77
Analysts	Strong Sell
Price Target	$4.83